<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>7(7)</volume><submitter>Jeyaraman M</submitter><pubmed_abstract>The contagiosity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has startled mankind and has brought our lives to a standstill. The treatment focused mainly on repurposed immunomodulatory and antiviral agents along with the availability of a few vaccines for prophylaxis to vanquish COVID-19. This seemingly mandates a deeper understanding of the disease pathogenesis. This necessitates a plausible extrapolation of cell-based therapy to COVID-19 and is regarded equivalently significant. Recently, correlative pieces of clinical evidence reported a robust decline in lymphocyte count in severe COVID-19 patients that suggest dysregulated immune responses as a key element contributing to the pathophysiological alterations. The large granular lymphocytes also known as natural kille</pubmed_abstract><journal>Heliyon</journal><pagination>e07635</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8294777</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Bracing NK cell based therapy to relegate pulmonary inflammation in COVID-19.</pubmed_title><pmcid>PMC8294777</pmcid><pubmed_authors>Jain R</pubmed_authors><pubmed_authors>Chellappan DK</pubmed_authors><pubmed_authors>Channaiah Anudeep T</pubmed_authors><pubmed_authors>Jeyaraman M</pubmed_authors><pubmed_authors>Dilip SJ</pubmed_authors><pubmed_authors>Kesari KK</pubmed_authors><pubmed_authors>Dholpuria S</pubmed_authors><pubmed_authors>Dua K</pubmed_authors><pubmed_authors>Kumar D</pubmed_authors><pubmed_authors>Dureja H</pubmed_authors><pubmed_authors>Ojha S</pubmed_authors><pubmed_authors>Muthu S</pubmed_authors><pubmed_authors>Jha NK</pubmed_authors><pubmed_authors>Gupta G</pubmed_authors><pubmed_authors>Jha SK</pubmed_authors><pubmed_authors>Sushmitha ES</pubmed_authors><pubmed_authors>Bapat A</pubmed_authors><pubmed_authors>Gulati A</pubmed_authors><pubmed_authors>Singh SK</pubmed_authors></additional><is_claimable>false</is_claimable><name>Bracing NK cell based therapy to relegate pulmonary inflammation in COVID-19.</name><description>The contagiosity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has startled mankind and has brought our lives to a standstill. The treatment focused mainly on repurposed immunomodulatory and antiviral agents along with the availability of a few vaccines for prophylaxis to vanquish COVID-19. This seemingly mandates a deeper understanding of the disease pathogenesis. This necessitates a plausible extrapolation of cell-based therapy to COVID-19 and is regarded equivalently significant. Recently, correlative pieces of clinical evidence reported a robust decline in lymphocyte count in severe COVID-19 patients that suggest dysregulated immune responses as a key element contributing to the pathophysiological alterations. The large granular lymphocytes also known as natural kille</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Jul</publication><modification>2025-04-05T00:48:51.012Z</modification><creation>2022-02-11T11:15:17.69Z</creation></dates><accession>S-EPMC8294777</accession><cross_references><pubmed>34312598</pubmed><doi>10.1016/j.heliyon.2021.e07635</doi></cross_references></HashMap>